What sector does Astellas Pharma Inc. belong to?

Astellas Pharma Inc. operates in the Pharmaceuticals sector, specifically the Pharmaceutical industry, and is listed on the US markets.

What is the current share price of 4503?

As of the latest available quote, 4503 traded at ¥2,240.50. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of 4503?

Astellas Pharma Inc. has a price-to-earnings (P/E) ratio of about 13.81. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of 4503?

The market capitalisation of Astellas Pharma Inc. is approximately ¥4.01T.

Is Astellas Pharma Inc. profitable?

For its latest reported financial year, Astellas Pharma Inc. recorded a net profit margin of about 13.63%.

Does 4503 pay a dividend?

Astellas Pharma Inc. currently has a dividend yield of about 3.50%.

What is the return on equity (ROE) of 4503?

Astellas Pharma Inc. has a return on equity (ROE) of about 17.40%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of 4503?

Over the past 52 weeks, 4503 has traded between a low of ¥1,557.50 and a high of ¥2,717.00.

Astellas Pharma Inc.

4503 TSE Pharmaceuticals Pharmaceutical

TSE Prime

¥2,240.50

+0.61%

Delayed · cached 15 min

Fair value analysis

4503

Astellas Pharma Inc.

¥2,240.50

Close used for this calculation

¥3,809.34Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

71/100

Profitability21/25

Returns14/25

Balance Sheet16/25

Efficiency20/25

Growth25/25

Strong

Quality radar

Consensus fair value

¥3,809.34

Below FV

▲ +70.0% against the close used

Model range ¥1,808.07 – ¥5,568.38

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥1,808.07Fair value¥3,809.34Bull¥5,568.38

FairClose

52-week traded range

52W low ¥1,575.5052W high ¥2,657.50

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Astellas Pharma Inc. closed at ¥2,240.50, 41.2% below the consensus fair value of ¥3,809.34 drawn from 9 valuation models.

Financial DNA score 71/100 — Strong. P/E of 13.8x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

¥5,568.38

+148.5%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

¥1,808.07

-19.3%

√(22.5 × EPS × BVPS)

EPS=162.77, BVPS=892.63 · outside Graham range (P/E 13.8, P/B 2.5) — asset-light, treat as a rough floor

P/E Fair Value

¥3,255.40

+45.3%

EPS × 20x (sector P/E)

EPS=162.77, Sector P/E=20x

Peter Lynch (PEG)

¥3,875.55

+73.0%

EPS × Growth% (PEG = 1 is fair)

EPS=162.77, g=23.8%

EV/EBITDA

¥3,350.73

+49.6%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=382.63B

Dividend Discount (DDM)

¥4,210.35

+87.9%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=77.97, r=10%, g=8%

Book Value (P/B)

¥2,543.99

+13.5%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=892.63, ROE=17.4%, g=6%, r=10%

Reverse DCF

¥2,240.50

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 2.1% | Historical: 23.8%

Margin of Safety

¥2,657.96

+18.6%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=3543.95, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer